Sanchis Gomar, Fabián Lucía, Alejandro
'Mitotherapy' for Heart Failure. [comentario] - Trends in molecular medicine, 2016 - 22(4):267-9.
Formato Vancouver:
Sanchís Gomar F, Lippi G, Lucía A. 'Mitotherapy' for Heart Failure. Trends Mol Med. 2016 Apr;22(4):267-9.
PMID: 26965961
Contiene 12 referencias
Abnormalities in mitochondrial dynamics along with those for the molecular mediators involved are presently being viewed with increased interest in the field of cardiovascular disease. Recent research highlights OPA1, a dynamin-like GTPase mediating mitochondrial fusion, as well as the 'mitoproteases' OMA1 and YME1L, as potential therapeutic targets against heart failure.
'Mitotherapy' for Heart Failure. [comentario] - Trends in molecular medicine, 2016 - 22(4):267-9.
Formato Vancouver:
Sanchís Gomar F, Lippi G, Lucía A. 'Mitotherapy' for Heart Failure. Trends Mol Med. 2016 Apr;22(4):267-9.
PMID: 26965961
Contiene 12 referencias
Abnormalities in mitochondrial dynamics along with those for the molecular mediators involved are presently being viewed with increased interest in the field of cardiovascular disease. Recent research highlights OPA1, a dynamin-like GTPase mediating mitochondrial fusion, as well as the 'mitoproteases' OMA1 and YME1L, as potential therapeutic targets against heart failure.
